Clinical Trials
62 trialsTrial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
FluBuATG
Dartmouth-Hitchcock Medical Center
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Memorial Sloan Kettering Cancer Center
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
Bellicum Pharmaceuticals
HaploOnly
University of Rochester
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
RACE
Celgene
ToTem
University College, London
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
University of Maryland, Baltimore
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
University of Pittsburgh
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Phase I Study of Sequential Cord Blood Transplants
Massachusetts General Hospital
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
4SC AG
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Indiana University
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Rutgers, The State University of New Jersey
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Pyroxamide in Treating Patients With Advanced Cancer
Memorial Sloan Kettering Cancer Center
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
A Phase I Trial of ZIO-101 in Hematologic Cancers
Alaunos Therapeutics